SC, I saw a pair of Cerwin Vegas recently at a local thrift shop, perfect condition for $10 each. I was tempted but they're large, almost like another piece of furniture, and the bass is too loud if you live in a condo. I haven't been listening to music too much lately, except in the car or via an MP3, but the Cerwin Vegas have a real nice sound.
>> Bishop Briggs <<
I wasn't familiar with her, but wow, what a talent. There are so many new people out there in music today, guess I'm way behind the curve. Check out this Johnny Cash song from 1976. In college that year in Michigan some of us hitchhiked to see him in concert -
Another update of interim data from AVXL, and another hit piece from Feuerstein, lol. I wouldn't be as dismissive as he is, since to be commercially successful, AVXL's AD drug only has to be slightly better than Aricept (which is to say slightly better than nothing). But until AVXL runs a placebo controlled study there's no way to gauge the efficacy of their drug in slowing the rate of cognitive decline in AD.
This could actually be a buying opportunity for a near/mid term bounce (though more near term downside is also possible), but beyond that you'll need to have a long time frame since they haven't even started a controlled trial yet -
>>> Anavex Alzheimer's Drug Plays Losing Game Against the Placebo Effect
Shares of Anavex Life Sciences (AVXL) plunged Wednesday because the months-long stock promotion campaign claiming a cure for Alzheimer's disease lost its sizzle.
A small group of Alzheimer's patients treated with Anavex's experimental drug Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time, according to updated results of a clinical trial presented Wednesday.
Anavex, in a press release, claims the Alzheimer's patients are "stable" over 31 weeks of treatment with 2-73 and that this is a "positive outcome."
But a scientific poster of the study data presented at the Alzheimer's Association International Conference shows 31-week declines in the patients' MMSE score, a measure of memory loss, and the ADCS-ADL, an assessment of daily living activities.
Last fall, Anavex presented data showing Alzheimer's patients treated with 2-73 for five weeks had improvements on five of six cognitive tests. After 31 weeks of treatment, only 3 of the 6 cognitive tests showed improvement.
Anavex shares fell 32% to $5.07 after the new 2-73 Alzheimer's data were disclosed Wednesday afternoon. The stock traded over $8 per share, essentially doubling in price, in the days leading up to the updated 2-73 study results.
The stock exhibited the same pump-and-dump trading pattern last fall when results from the 2-73 study were first presented.
Bad clinical trials produce bad data, and Anavex is conducting a garbage study.
The only way to produce credible data in Alzheimer's is to conduct randomized, double-blind, placebo-controlled studies. One group of patients is randomized to receive a drug, the other group of patients received a placebo. Neither the patients nor their doctors know which arm of the study they're in. These studies need to run for at least one year because it takes that long to detect meaningful changes in memory, cognition and functions of daily living of patients.
Even when a company designs an Alzheimer's clinical trial correctly, the failure rate is basically 100%. Ask TauRx Therapeutics.
The Anavex study is small -- just 32 patients enrolled -- and lacks a control arm of any kind. All the patients were selected and enrolled at a single hospital in Australia. All were treated with 2-73.
The handful of Alzheimer's patients in the Anavex study improved over a short period of time, as shown last fall, because they were easily convinced the drug they were taking would help them. But as shown Wednesday, that placebo effect is wearing off.
News 
Market Data 
Discover 
AI
